Singapore's Health Sciences Authority flagged four products found with banned or potent ingredients, with a user of one such ...
Initiated analytical studies in Q4 2024 to prepare for a potential Biosimilar Biological Product Development ("BPD") Type 2a meeting with the FDA in the second half of 2025 - - Pursuing a 351(k) regul ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback